Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00219063 · ClinicalTrials.gov registry record · Phase 3
A Clinical Study to Compare an Aliskiren Based Hypertensive Regimen With a Ramipril Based One Followed by a Randomized Withdrawal.
A Phase 3 study of Hypertension, sponsored by Novartis.
- Completed
- Registry status
- Phase 3
- Development phase
- 844
- Enrollment target
- 1
- Study location
NCT00219063: Completed Phase 3 study of Hypertension, sponsored by Novartis.
NCT00219063 is a Phase 3 study of Hypertension that has completed, run by Novartis. The registered enrollment target is 844 participants, below the 3,506-participant average among 470 other Hypertension trials with a reported enrollment target (76% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00219063, a Phase 3 study of Hypertension, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 844 participants
- Enrollment target
- 1
- Study location
Study Summary
To compare the aliskiren regimen versus the ramipril regimen on reduction in Blood Pressure.
Conditions Studied
Interventions
- DRUG aliskiren
Study Locations (1)
New Jersey
- Novartis Pharmaceuticals - East Hanover
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 844 participants |
| Start Date | 2005-02 |
| Est. Completion | 2006-03 |
| Phase | Phase 3 |
What the finished NCT00219063 record still lists
NCT00219063 is an interventional study that assigns participants to a tested intervention. The registered 844 participants enrollment target is mid-sized for trials with a published cap, below the 3,506-participant average among 470 other Hypertension trials with a reported enrollment target (76% lower).
The record links to 1 condition, with Hypertension appearing as the primary indexed condition, and to 1 intervention - of which aliskiren is the first listed.
NCT00219063 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT00219063 about?
NCT00219063 is a clinical study titled "A Clinical Study to Compare an Aliskiren Based Hypertensive Regimen With a Ramipril Based One Followed by a Randomized Withdrawal.". To compare the aliskiren regimen versus the ramipril regimen on reduction in Blood Pressure.
What is the current status of trial NCT00219063?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 844 participants. The study started on 2005-02. Estimated completion is 2006-03.
What conditions does trial NCT00219063 study?
This clinical trial studies the following conditions: Hypertension.
What interventions are being tested in trial NCT00219063?
The interventions under investigation include: aliskiren (DRUG).
Who is sponsoring clinical trial NCT00219063?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00219063 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00219063's enrollment target sits among peer trials
844 84th of 470 higher than 387 of 470 other Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
RECRUITING · Phase 3
-
Renal Artery Denervation Assessment Without Antihypertensive Medication Regimen (RADAR)
RECRUITING · Phase 3
-
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
RECRUITING · Phase 3
-
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
RECRUITING · Phase 3
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
RECRUITING · Phase 3
-
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06747949 · 844 participants · Phase 3
A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)
- NCT02757859 · 845 participants · NA
High Volume Washing of the Abdomen in Increasing Survival After Surgery in Patients With Pancreatic Cancer That Can Be Removed by Surgery
- NCT06439979 · 843 participants · NA
Rural Adult and Youth Sun Protection Study
- NCT06027788 · 842 participants · NA
CTSN Embolic Protection Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia